You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
ZNL 02-096 最新
生物活性 for ZNL 02-096
ZNL 02-096 is a potent and selective Wee1 Degrader (PROTAC®) that comprises the Wee1 inhibitor AZD 1775 joined by a linker to the cereblon-binding ligand Pomalidomide (Cat. No. 6302). ZNL 02-096 selectively degrades Wee1 at submicromolar concentrations, while sparing PLK1, an AZD 1775 secondary target. In MOLT-4 cells in vitro, ZNL 02-096 induces degradation of Wee1, accumulation of DNA damage, arrest of the cell cycle in the G2/M phase and apoptosis. The compound shows antiproliferative effects in a panel of 300 cancer cell lines.
PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Sold under license from Dana-Farber Cancer Institute.
技术数据 for ZNL 02-096
|储存||Store at -20°C|
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for ZNL 02-096
|溶剂||最高浓度 mg/mL||最高浓度 mM|
制备储备液 for ZNL 02-096
以下数据基于产品分子量 799.89。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|浓度/溶剂体积/质量||1 mg||5 mg||10 mg|
|0.5 mM||2.5 mL||12.5 mL||25 mL|
|2.5 mM||0.5 mL||2.5 mL||5 mL|
|5 mM||0.25 mL||1.25 mL||2.5 mL|
|25 mM||0.05 mL||0.25 mL||0.5 mL|
参考文献 for ZNL 02-096
Li et al (2020) Development and characterization of a Wee1 kinase degrader. Cell Chem.Biol. 27 57 PMID: 31735695
If you know of a relevant reference for ZNL 02-096, please let us know.
关键词: ZNL 02-096, ZNL 02-096 supplier, ZNL02-096, Wee1, Degrader, PROTAC, PROTACs, AZD, 1775, selective, TPD, targeted, protein, degradation, Active, Degraders, Checkpoint, Kinases, Control, 7240, Tocris Bioscience
篇 ZNL 02-096 的引用文献
引用文献是使用了 Tocris 产品的出版物。
目前没有 ZNL 02-096 的引用文献。 您是否知道使用了 Tocris ZNL 02-096 的优秀论文？ 请告知我们.
ZNL 02-096 的评论
目前没有该产品的评论。 Be the first to review ZNL 02-096 and earn rewards!
Have you used ZNL 02-096?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
Targeted Protein Degradation Research Product Guide
This brochure highlights the tools and services available from Bio-Techne to support Targeted Protein Degradation research, including:
- Active Degraders
- Degrader Building Blocks
- Custom Degrader Services
- UPS Proteins and Assays
- Assays for Protein Degradation
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Epigenetics in Cancer Poster
Adapted from the 2015 Cancer Product Guide Edition 3, this poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Targeted Protein Degradation Poster
Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia